Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company based in the Seattle, Washington area, dedicated to developing small molecule therapeutics aimed at restoring neuronal health and slowing neurodegeneration. Athira's innovative pipeline includes several promising compounds, particularly targeting the neurotrophic hepatocyte growth factor (HGF) system, which plays a crucial role in nervous system maintenance and repair.
The company’s lead candidate, Fosgonimeton (ATH-1017), is a subcutaneously administered small molecule designed to positively modulate the HGF/MET system. It is currently being evaluated in the Phase 2/3 LIFT-AD clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, with topline data expected in the second half of 2024. Fosgonimeton has shown potential in enhancing neuroprotective, neurotrophic, and anti-inflammatory pathways, which are critical in combating neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
In addition to Fosgonimeton, Athira’s pipeline includes ATH-1105 and ATH-1020, both designed to be orally available treatments enhancing the HGF/MET system. ATH-1105 is particularly promising in preclinical models of amyotrophic lateral sclerosis (ALS), demonstrating significant neuroprotective effects, enhanced survival, and improved motor and nerve functions. The company plans to initiate first-in-human studies for ATH-1105 in the first half of 2024.
Athira's research is bolstered by funding from notable organizations such as the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, and Dolby Family Ventures. This support underscores the company’s strong financial position and its capacity to advance its therapeutic candidates through key development milestones.
Recent updates highlight the therapeutic potential of Athira’s small molecules. For instance, fosgonimeton has demonstrated promising results in preclinical models of Alzheimer’s and Parkinson’s diseases, showing neuroprotective effects and improvement in cognitive and motor functions. Additionally, ATH-1105's preclinical studies have shown consistent beneficial effects in ALS models, reinforcing Athira’s approach and commitment to developing novel therapies for neurodegenerative diseases.
Athira is also active in the scientific community, regularly presenting its findings at major conferences and publishing in peer-reviewed journals. The company’s efforts are focused on leveraging its patented technologies to develop cost-effective treatments that address the root causes of neurodegenerative diseases, setting it apart from competitors that primarily target disease symptoms.
For more information about Athira Pharma, Inc., visit www.athira.com and follow the company on Facebook, LinkedIn, X (formerly known as Twitter), and Instagram.
Athira Pharma (NASDAQ: ATHA) appointed Rachel Lenington as Chief Technology Officer, effective June 14, 2021. Lenington brings over 20 years of experience from organizations like Seagen Inc and the Bill & Melinda Gates Foundation. Her expertise in R&D, drug development, and commercialization is expected to bolster Athira's efforts in neurodegenerative disease treatments. CEO Leen Kawas expressed optimism about her leadership enhancing the company's product strategies. Athira focuses on developing small molecules to restore neuronal health, notably its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s dementia.
Athira Pharma (NASDAQ: ATHA) announced its participation in two upcoming investor conferences: the JMP Securities Life Sciences Conference on June 17, 2021, at 3:30 PM ET and the Raymond James Human Health Innovation Conference on June 21, 2021, at 1:20 PM ET. Management will engage in discussions about neurodegenerative diseases, focusing on new therapeutic targets for conditions like Alzheimer’s and Parkinson’s. Webcasts of the presentations will be available on the company’s website for 30 days post-event.
Athira Pharma, Inc. (NASDAQ: ATHA) has appointed Mark Worthington as General Counsel, effective June 1, 2021. Worthington brings extensive legal experience from 24 years at Summit Law Group, particularly in corporate finance and governance. His role is expected to bolster Athira’s strategic business growth, as cited by CEO Leen Kawas. Athira is focused on developing therapies aimed at neurodegenerative disorders, with its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s disease.
Athira Pharma (NASDAQ: ATHA) announced participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. CEO Leen Kawas will engage in a fireside chat and one-on-one investor meetings during these events. Details include the fireside chat at the Jefferies Conference at 4:30 PM ET and the Goldman Sachs Conference at 5:30 PM ET. Webcasts for both events are available on the Athira website, with archived replays accessible for at least 30 days following each event.
Athira Pharma, Inc. (NASDAQ: ATHA) reported financial results for Q1 2021, highlighting a net loss of $8.9 million, or $0.25 per share. The company's cash position improved to $357.7 million following a successful follow-on public offering, raising $103.5 million. Athira is advancing its clinical trials for ATH-1017 in treating Alzheimer’s and Parkinson’s disease dementia, with Phase 2 trials expected to start by late 2021. The company remains focused on developing small molecules aimed at neurodegeneration, maintaining a clear strategic plan and ample funding for future milestones.
Athira Pharma (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company, announced that CEO Leen Kawas, Ph.D., will participate in the Sachs 4th Annual Neuroscience Innovation Forum on April 28, 2021, at 8:30 a.m. PT. The panel titled “Progress in Alzheimer’s and Dementia” will focus on advancements in treating neurodegenerative diseases. The event will also feature notable experts from AZTherapies, NIH, Johnson & Johnson Innovation, and more. A recording will be available starting May 26, and further details can be found on Athira's website.
Athira Pharma (NASDAQ: ATHA) is hosting a webinar on April 15, 2021, at 1:30 p.m. PT to discuss its therapeutic approach targeting the HGF/MET pathway for neurodegeneration. Led by neurologist Marwan Sabbagh, M.D., the session will cover Alzheimer’s and dementia treatment landscapes and the role of hepatocyte growth factor in brain health. Kevin Church, Ph.D., will provide insights on Athira's lead candidate, ATH-1017, designed to enhance HGF/MET activity. Registration is available on Athira’s investor website, and a replay will be accessible for 30 days post-event.
Athira Pharma reported significant developments in its clinical trials and financial status as of March 25, 2021. The company is actively enrolling patients in LIFT-AD and ACT-AD studies for its investigational drug ATH-1017, aimed at treating Alzheimer’s disease. Notably, Athira raised $103.5 million in a follow-on public offering. Financially, the net loss for 2020 was $19.9 million, with cash reserves of $268.2 million expected to sustain operations through at least 2022. The firm anticipates IND submissions for Parkinson’s disease dementia and neuropsychiatric programs by the end of 2021.
Athira Pharma (NASDAQ: ATHA), a biopharmaceutical company focused on neuronal health, announced that its CEO, Leen Kawas, will participate in a virtual fireside chat at Stifel’s 3rd Annual CNS Conference on April 1, 2021, at 9:00 am ET. The event will be accessible via a live webcast on Athira's investor relations website, with an archived replay available for 90 days post-event. Athira is advancing its lead candidate, ATH-1017, targeting Alzheimer's and Parkinson's dementia, aiming to alter the course of neurological diseases and enhance cognitive abilities.
Athira Pharma (NASDAQ: ATHA) will participate in the virtual Life Science Innovation Northwest Conference on March 30-31, 2021. CEO Leen Kawas will discuss new treatments for Alzheimer's disease and neurodegeneration in a panel at 12:30 p.m. PT on March 30, moderated by Paul Matteis. Kevin Church will present a corporate overview from 1:35 to 3:00 p.m. PT on the same day. Both events will be webcast live. Athira is focused on developing small molecules like ATH-1017 to restore neuronal health and combat neurodegeneration.
FAQ
What is the current stock price of Athira Pharma (ATHA)?
What is the market cap of Athira Pharma (ATHA)?
What is Athira Pharma, Inc.?
What are Athira's lead compounds?
What is the focus of Athira's research?
When are the next significant milestones for Athira?
Who funds Athira's research?
What differentiates Athira's approach from other companies?
What is Fosgonimeton?
What recent achievements has Athira reported?
How does Athira contribute to the scientific community?
Where can I find more information about Athira Pharma?
